Publication Name	World Journal of Hepatology
Manuscript ID	74948
Country	Japan

Received	2022-01-12 07:27
Peer-Review Started	2022-01-12 07:28
First Decision by Editorial Office Director	2022-03-16 03:17
Return for Revision	2022-03-16 03:17
Revised	2022-03-18 06:13
Publication Fee Transferred
Second Decision by Editor	2022-05-23 03:28
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2022-05-28 07:12
Articles in Press	2022-05-28 07:12
Edit the Manuscript by Language Editor	2022-05-17 23:11
Typeset the Manuscript	2022-05-30 07:40
Publish the Manuscript Online	2022-06-23 14:39

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Study
Article Title	Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Kazuto Tajiri, Hiroyuki Ito, Kengo Kawai, Yoshiro Kashii, Yuka Hayashi, Aiko Murayama, Masami Minemura, Terumi Takahara, Yukihiro Shimizu and Ichiro Yasuda
ORCID	Author(s) ORCID Number Kazuto Tajiri http://orcid.org/0000-0002-2373-8601 Hiroyuki Ito http://orcid.org/0000-0001-7356-8527 Kengo Kawai http://orcid.org/0000-0003-3465-1293 Yoshiro Kashii http://orcid.org/0000-0002-4813-9699 Yuka Hayashi http://orcid.org/0000-0003-4992-1161 Aiko Murayama http://orcid.org/0000-0003-1084-3012 Masami Minemura http://orcid.org/0000-0001-7489-7955 Terumi Takahara http://orcid.org/0000-0002-2363-671X Yukihiro Shimizu http://orcid.org/0000-0002-8216-9269 Ichiro Yasuda http://orcid.org/0000-0002-6888-0310
Funding Agency and Grant Number
Corresponding Author	Kazuto Tajiri, MD, PhD, Associate Professor, Department of Gastroenterology, Toyama University Hospital, 2630 Sugitani, Toyama 930-0194, Japan. tajikazu@med.u-toyama.ac.jp
Key Words	Direct acting antivirals; Hepatitis C virus; Hepatocellular carcinoma; Recurrence; Liver fibrosis; Curative treatment
Core Tip	To estimate the therapeutic value of direct-acting antivirals (DAA) in hepatitis C virus (HCV)-infected patients with a history of hepatocellular carcinoma (HCC), the clinical course of HCV patients with or without a history of HCC after DAA therapy was retrospectively analyzed. DAA treatment did not increase the incidence rate of HCC recurrence/occurrence or enhance malignant transformation of HCC in patients with a history of HCC. The risk of HCC recurrence after DAA therapy was significantly associated with the frequency of HCC recurrence/occurrence before DAA therapy.
Publish Date	2022-06-23 14:39
Citation	Tajiri K, Ito H, Kawai K, Kashii Y, Hayashi Y, Murayama A, Minemura M, Takahara T, Shimizu Y, Yasuda I. Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma. World J Hepatol 2022; 14(6): 1190-1199
URL	https://www.wjgnet.com/1948-5182/full/v14/i6/1190.htm
DOI	https://dx.doi.org/10.4254/wjh.v14.i6.1190

Full Article (PDF)	WJH-14-1190.pdf
Full Article (Word)	WJH-14-1190.docx